Pretransplant characteristics of patients who underwent allogeneic hematopoietic cell transplantation in the overall cumulative incidence estimation cohort (n = 1857)
| . | Values . |
|---|---|
| Patient demographics | |
| Age, y, median (IQR) | 53 (42-61) |
| Female sex, n (%) | 779 (42.0) |
| White race, n (%) | 1598 (86.1) |
| Prior autologous transplant, n (%) | 305 (16.4) |
| BMI in kg/m2, median (IQR) | 27 (24-30) |
| <29.9 (not obese), n (%) | 1376 (74.1) |
| 30 to 34.9 (obese class 1), n (%) | 315 (17.0) |
| 35 to 39.9 (obese class 2), n (%) | 96 (5.2) |
| ≥40.0 (obese class 3), n (%) | 70 (3.8) |
| Type of VTE history, n (%) | |
| None | 1644 (88.5) |
| CR-DVT | 112 (6.0) |
| PE or LE-DVT | 101 (5.4) |
| Timing of VTE history, n (%) | |
| None | 1644 (88.5) |
| VTE >6 mo prior to transplant | 97 (5.2) |
| VTE within 6 mo prior to transplant | 117 (6.3) |
| HCT–comorbidity index score, n (%) | |
| 0 | 268 (14.4) |
| 1 to 2 | 525 (28.3) |
| ≥3 | 905 (48.7) |
| Missing | 159 (8.6) |
| Disease type, n (%) | |
| Leukemia | 1434 (77.2) |
| Lymphoma | 247 (13.3) |
| Myeloma | 111 (6.0) |
| Other | 65 (3.5) |
| Donor match, n (%) | |
| Matched related | 599 (32.3) |
| Matched unrelated | 769 (41.4) |
| Mismatched related | 104 (5.6) |
| Mismatched unrelated | 222 (12.0) |
| Umbilical cord blood | 163 (8.8) |
| Conditioning regimen, n (%) | |
| Nonmyeloablative (reduced intensity) | 808 (43.5) |
| Myeloablative without high-dose TBI | 731 (39.4) |
| Myeloablative with high-dose TBI (≥1200 cGy) | 318 (17.1) |
| GVHD prophylaxis | |
| Tacrolimus | 961 (51.7) |
| Cyclosporine | 752 (40.5) |
| Sirolimus + tacrolimus or cyclosporine | 106 (5.7) |
| Others | 38 (2.1) |
| . | Values . |
|---|---|
| Patient demographics | |
| Age, y, median (IQR) | 53 (42-61) |
| Female sex, n (%) | 779 (42.0) |
| White race, n (%) | 1598 (86.1) |
| Prior autologous transplant, n (%) | 305 (16.4) |
| BMI in kg/m2, median (IQR) | 27 (24-30) |
| <29.9 (not obese), n (%) | 1376 (74.1) |
| 30 to 34.9 (obese class 1), n (%) | 315 (17.0) |
| 35 to 39.9 (obese class 2), n (%) | 96 (5.2) |
| ≥40.0 (obese class 3), n (%) | 70 (3.8) |
| Type of VTE history, n (%) | |
| None | 1644 (88.5) |
| CR-DVT | 112 (6.0) |
| PE or LE-DVT | 101 (5.4) |
| Timing of VTE history, n (%) | |
| None | 1644 (88.5) |
| VTE >6 mo prior to transplant | 97 (5.2) |
| VTE within 6 mo prior to transplant | 117 (6.3) |
| HCT–comorbidity index score, n (%) | |
| 0 | 268 (14.4) |
| 1 to 2 | 525 (28.3) |
| ≥3 | 905 (48.7) |
| Missing | 159 (8.6) |
| Disease type, n (%) | |
| Leukemia | 1434 (77.2) |
| Lymphoma | 247 (13.3) |
| Myeloma | 111 (6.0) |
| Other | 65 (3.5) |
| Donor match, n (%) | |
| Matched related | 599 (32.3) |
| Matched unrelated | 769 (41.4) |
| Mismatched related | 104 (5.6) |
| Mismatched unrelated | 222 (12.0) |
| Umbilical cord blood | 163 (8.8) |
| Conditioning regimen, n (%) | |
| Nonmyeloablative (reduced intensity) | 808 (43.5) |
| Myeloablative without high-dose TBI | 731 (39.4) |
| Myeloablative with high-dose TBI (≥1200 cGy) | 318 (17.1) |
| GVHD prophylaxis | |
| Tacrolimus | 961 (51.7) |
| Cyclosporine | 752 (40.5) |
| Sirolimus + tacrolimus or cyclosporine | 106 (5.7) |
| Others | 38 (2.1) |